Lorlatinib for the Treatment of Non-Small Cell Lung Cancer Compassionate use IND
These patients report a very good quality of life with a good performance status and are therefore very motivated to proceed with further systemic treatments. At this time the only other standard treatments include immunotherapy or ceritinib. With regard to ceritinib, while this is a FDA approved medication there is no evidence to date which has tested its efficacy following administration of alectinib. Therefore, this would only add to toxicity without any known efficacy.
For the above reasons the use of Lorlatinib is ideal. It is an oral therapy with exquisite activity against ALK, and in particular, against brain metastases.
Non-Small Cell Lung Cancer
Please see appendices 7.1 and 7.2
18 - 100
Healthy Volunteers Needed
Duration of Participation
Until disease progression then 30-day follow-up visit
OHSU Knight Cancer Institute Information line 503-494-1080